Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma

Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy for the treatment of immune checkpoint therapy-resistant/refractory advanced melanoma patients. However, its safety and efficacy remain to be determined among patients with concurrent chronic lymphocytic leukemia (CLL)/small lymph...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lilit Karapetyan, Joel Kuriakose, Matthew C. Perez, Johannes R. Ali, MacLean S. Hall, Matthew S. Beatty, Christopher D. Otteni, Jin Xu, Denise Kalos, Carlos Moran-Segura, Ella Vieira, Karla Adams, Lianicet Rodriguez-Alfonso, Elizabeth C. DiMaggio, Hanna Bailey, Javier Pinilla-Ibarz, Frederick L. Locke, John E. Mullinax, Pei-Ling Chen, Jinming Song, Jane L. Messina, Douglas B. Johnson, David S. Morgan, Zeynep Eroglu, Nikhil I. Khushalani, Vernon K. Sondak, Amod A. Sarnaik, Kenneth Tsai, James J. Mulé, Shari Pilon-Thomas
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-11-01
Edice:	Frontiers in Immunology
Témata:	melanoma tumor infiltrating lymphocytes chronic lymphocytic leukemia/small lymphocytic lymphoma cell therapy adoptive cell immunotherapy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1718443/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!